Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.58 |
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413271 | 1.00 | IDO1 (0.58) | IDO1PNMTTAAR1SIGMAR1CYP4F2 | |
| SCHEMBL1964765 | 0.97 | IDO1 (0.56) | IDO1PNMTTAAR1SIGMAR1CYP4F2 | |
| SCHEMBL27276965 | 0.91 | TP53 (0.61) | IDO1PNMTTAAR1SIGMAR1CYP4F2 | |
| SCHEMBL4962307 | 0.82 | SIGMAR1 (0.45) | IDO1PNMTTAAR1SIGMAR1POLB | |
| SCHEMBL30019331 | 0.80 | PNMT (0.61) | IDO1PNMTTAAR1SIGMAR1IGF1R | |
| SCHEMBL507167 | 0.80 | CYP4F2 (0.43) | IDO1PNMTTAAR1SIGMAR1CYP4F2 | |
| SCHEMBL507688 | 0.80 | CYP4F2 (0.40) | IDO1PNMTTAAR1CYP4F2CYP4A11 | |
| SCHEMBL177296 | 0.80 | PNMT (0.61) | IDO1PNMTTAAR1SIGMAR1IGF1R | |
| SCHEMBL30595364 | 0.80 | CYP4F2 (0.40) | IDO1PNMTTAAR1CYP4F2CYP4A11 | |
| SCHEMBL30488129 | 0.80 | CYP4F2 (0.43) | IDO1PNMTTAAR1SIGMAR1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111004228-B | GSK-3 beta/ChE double inhibitor and preparation method and application thereof | 中国药科大学 | 2023-05-23 | — | — | CN | claimed |
| WO-2021047572-A1 | GSK-3β/CHE DOUBLE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国药科大学 | 2021-03-18 | — | — | WO | claimed |
| CN-111004228-A | GSK-3 β/ChE dual inhibitor and preparation method and application thereof | 中国药科大学 | 2020-04-14 | — | — | CN | claimed |
| EP-4741397-A1 | FUSED TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Zhongge Biological Technology Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025243042-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILIN D | THE UNIVERSITY OF LIVERPOOL (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4629980-A1 | ANTIMICROBIAL COMPOUNDS | SRI International (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250205195-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | AMTIXBIO CO., LTD. (KR) | 2025-06-26 | — | — | US | disclosed |
| US-4279920-A | 2,2-Dimethyl-3-(2-bromo-2-phenyl-vinyl)-cyclopropanecarboxylic acid 3-phenoxybenzyl esters and pesticidal use | BAYER AKTIENGESELLSCHAFT (DE) | 1981-07-21 | — | — | US | disclosed |
| EP-0001439-B1 | 1-N-SUBSTITUTED 1.4-DIHYDROPYRIDAZINE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE FOR PHARMACEUTICALS | BAYER AG (DE) | 1981-01-28 | — | — | EP | disclosed |
| US-RE30420-E | DIURETIC, HYPOTENSIVE | BAYER AKTIENGESELLSCHAFT (DE) | 1980-10-21 | — | — | US | disclosed |
| EP-0001439-A1 | 1-N-substituted 1.4-dihydropyridazine derivatives, method for their preparation and their use for pharmaceuticals | BAYER AG (DE) | 1979-04-18 | — | — | EP | disclosed |
| US-4112227-A | DIURETIC, SALURETIC, ANTIHYPERTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-05 | — | — | US | disclosed |
| US-4056533-A | HYPOTENSIVE AGENTS, ANTICOAGULANTS, DIURETICS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-01 | — | — | US | disclosed |
| US-4000294-A | DIURESIS OR SALURESIS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-28 | — | — | US | disclosed |
| US-3992404-A | DIURETICS, SALURETICS, ANTIHYPERTENSIVE AGENTS, AND ANTITHROMBOTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-16 | — | — | US | disclosed |
| US-3952008-A | DIURETIC, SALURETIC, HYPOTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | IDO1 2279/4885PNMT 3622/4885TAAR1 579/4885 |
| US-12473314-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | IDO1 3203/4885PNMT 665/4885TAAR1 4464/4885 |
| US-20250205195-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | TSLP, IL2RA, TRPC7 | IDO1 781/4885PNMT 1638/4885TAAR1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.